Search the Newsreel

Pluri Inc (PLUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pluri Inc (PLUR), highlighting its current price momentum score of 4.86 and its position between resistance at $1.92 and support at $1.32, suggesting suitability for range-bound swing trading. It details various technical indicators like MACD, RSI, and …

Pluri Inc (PLUR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Pluri Inc (PLUR), highlighting its current risk score of 2.15, which ranks 234 out of 384 in the Biotechnology & Medical Research industry. It details the company's beta value of 0.66, indicating underperformance in rising markets and …

Pluri Inc. Revenue Breakdown – FWB:4DX

This article provides a revenue breakdown for Pluri Inc. (FWB:4DX), highlighting that the largest contribution to its revenue came from Israel, generating 1.13 million EUR last year and 304.35K EUR the year prior. The information is presented within the financial overview section of TradingView.

Pluri Inc (PLUR) Financial Health: Profitability & Balance Sheet Analysis

Pluri Inc (PLUR) has a weak financial status and low operating efficiency, ranking 368 out of 384 in the Biotechnology & Medical Research industry with a financial score of 5.27. The company's latest quarterly revenue decreased by 60.89% year-over-year, and its net profit saw …

Pluri subsidiary completes UK regulatory registration for aesthetics product By Investing.com

Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has secured regulatory registration in the UK for its regenerative aesthetics product, Regenativo+. This registration allows commercial marketing of Regenativo+ in the UK market, estimated at $900 million in 2026, and follows previous regulatory progress in …

Pluri Inc (PLUR) Income Statement

This article provides the quarterly and annual income statements for Pluri Inc (PLUR), allowing users to analyze the company's financial performance and operational efficiency. It presents detailed data on various financial metrics, including total revenue, operating expenses, net income, and earnings per share over …

Pluri's subsidiary Cellav completes UK regulatory registration for regenerative aesthetics product launch.

Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has successfully registered its regenerative aesthetics product, Regenativo+, in the UK, paving the way for commercial launch in the $900 million annual market. This move is a key part of Cellav's international expansion, leveraging Pluri's 3D …

Pluri’s Cellav Secures UK Cosmetic Registration for Regenativo+ Ahead of Regenerative Aesthetics Launch

Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has secured UK regulatory registration for its regenerative aesthetics product, Regenativo+. This approval allows Cellav to launch Regenativo+ in the UK's approximately $900 million annual market, marking a key step in Pluri's global expansion strategy for …

Pluri’s Regenativo+ Is Registered for Sale in a $900M UK Market

Pluri's subsidiary, Cellav, has successfully completed the cosmetic regulatory registration for its regenerative aesthetics product, Regenativo+, in the UK. This registration, notified on the UK Cosmetic Product Notification portal, allows Cellav to commercially market the product in the UK, a market estimated at $900 …

Pluri Inc (PLUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Pluri Inc (PLUR), covering business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant data for these categories. The page also displays current stock information and market cap for …

Pluri Inc. (PLUR) Gains Slightly as Stock Tests Key Resistance Near $1.76 - Wave Equality

PLUR|Pluri Inc|Price:1.640|

Pluri Inc (PLUR) has weak fundamentals but significant growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Institutional ownership is high, and while analysts have a high price target of $12.00, the stock is expected to trend down …

PLUR|Pluri Inc|Price:1.780|Chg%:-0.040

Pluri Inc., formerly Pluristem Therapeutics Inc., is an Israeli company specializing in cell-based products and technologies for various industries including pharmaceuticals, food, and agriculture. The company focuses on cell transformation and 3D cell expansion to mass-produce cells, holding over 140 patents. Key executives include …

Pluri Inc (PLUR) Cash Flow

This article provides a detailed cash flow statement for Pluri Inc (PLUR), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures ranging from FY2012Q1 to FY2026Q3, along with definitions and FAQs for understanding different types of cash flow …

Pluri Inc (PLUR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pluri Inc (PLUR)'s dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years. The article also lists several stock merger events that occurred on March 27, 2024, with …

Pluri Inc (PLUR) Institutional Confidence

Pluri Inc (PLUR) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.56%, marking a quarter-over-quarter decrease of 14.97%. While James Simons is cited as the largest …

Pluri Inc (PLUR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Pluri Inc (PLUR), indicating its current valuation score is 8.52, ranking it 120th out of 386 in the Biotechnology & Medical Research industry. It notes the company's current P/E ratio is -0.61, which is below its recent …

Enterprise value to revenue forward of Pluri Inc. – NASDAQ:PLUR

The article focuses on the enterprise value to revenue forward for Pluri Inc. (NASDAQ: PLUR), providing this specific financial metric. It appears to list a particular value and its change over a period, though the actual numerical data is not present in the provided …

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

Pluri Chairman Alejandro Weinstein has increased his cumulative investment in the biotechnology company to over $17 million, raising his ownership to more than 30%. This significant investment, including a recent $1.25 million advance, underscores his confidence as Pluri shifts its strategy from platform development …

Price to book forward of Pluri Inc. – LS:A408KW

The article references the "Price to book forward" for Pluri Inc., identified by the stock symbol LS:A408KW on the Lang & Schwarz Tradecenter. It appears to be a stub or a very brief financial data point from TradingView, indicating that specific financial metrics for …

Pluri in ongoing talks to extend EIB financing

Pluri Inc. is in ongoing discussions with the European Investment Bank (EIB) to extend the repayment date of a €20 million loan, which was originally due on June 1, 2026. While talks are progressing constructively, there is still uncertainty regarding a definitive resolution and …

Pluri chairman raises stake above 30%; shares up

Pluri's chairman, Zami Aberman, has increased his stake in the company to over 30%, reflecting strong confidence in the biotech firm without triggering a mandatory tender offer. This significant acquisition led to an almost 10% rise in Pluri's shares. The company is actively developing …

Pluri Inc. (PLUR) Q2 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D Investment - Non-GAAP Earnings

Pluri Inc. Q2 2026 Earnings: Wider-than-Expected Loss Drives Stock Decline - Slow Growth Warning

Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In

Pluri Inc. 3Q 2026: Revenue $167K, Net income ($5.55M), EPS ($0.55) — 10-Q Summary

PLUR Q3'26 Earnings: EPS estimate is (0.66) USD

Pluri Inc. SEC 10-Q Report

Pluri Inc. Releases 2024 10-K Report Highlighting Strategic Growth and Operational Advances

Pluri Inc. (PLUR) stock price, news, quote and history

Pluri (PLUR) Earnings Date and Reports 2026 $PLUR